About Contact Us Careers

Chlamydia Treatment Market - Top Companies and Manufacturers

Request Free Sample Copy

Report ID: 3579
Published Date: Aug 26, 2024
Report Format: PDF, PPT

Buy Now

Companies Dominating the Chlamydia Landscape

Pfizer, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
GlaxoSmithKline Plc
AstraZeneca plc
Gilead Sciences Inc.
Sanofi Group
Teva Pharmaceuticals
Novartis AG
Abbott Laboratories
Hologic, Inc.
Johnson & Johnson Services, Inc.

Browse Key Market Insights with Data Illustration:

Chlamydia Market Size & Share, Growth Forecast 2036

In the News

October 2019- GSK began the phase III clinical program for new chemical class of antibiotic, gepotidacin, in patients with uncomplicated urinary tract infection and STDs.
August 2019- Statens Serum Institut, completed the clinical phase 1 trial for first-generation vaccine candidate (CTH522), which is aimed to provide a preventive therapy for chlamydia infection.

Author Credits: Radhika Pawar

Report ID: 3579
Published Date: Aug 26, 2024
Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of chlamydia is evaluated at USD 3.28 billion.

Chlamydia Market size was valued at USD 3.07 billion in 2023 and is set to cross USD 8.97 billion by 2036, expanding at more than 8.6% CAGR during the forecast period i.e., between 2024-2036. The market growth is driven by increasing prevalence of sexually transmitted diseases globally and rising demand for screening of chlamydia.

Asia Pacific industry is expected to account for largest revenue share by 2036, on account of growing demand for medical screening and burgeoning need for raising awareness about STIs.

The major players in the market are Pfizer, Inc., GlaxoSmithKline Plc, AstraZeneca plc, Gilead Sciences Inc., Sanofi Group, and others.

Inquiry Before Buying Request Free Sample